ArticleFrontiers in endocrinology2025
LC-MS-based conventional metabolomics combined with machine learning models to identify metabolic markers for the diagnosis of type I diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine Learning-Based Identification of Serum Metabolic Signatures in Adult Patients with Type 1 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Changes in certain metabolites are linked to an increased risk of type I diabetes (T1D), making metabolite analysis a valuable tool for T1D diagnosis and treatment. This study aimed to identify a metabolic signature linked with T1D. Methods: Untargeted metabolomic profiling was performed using liquid chromatography-mass spectrometry (LC-MS) on peripheral blood samples from T1D patients (n = 45) and healthy controls (n = 40). Data preprocessing and quality control were conducted using MetaboAnalyst 4.0. Differential metabolites (DMs) were identified via Wilcoxon rank-sum test (P< 0.05), and key diagnostic markers were selected using least absolute shrinkage and selection operator (LASSO) regression. A streptozotocin (STZ)-induced diabetic rat model was used for Results: A total of 157 annotated metabolites were detected (58 in ESI- and 99 in ESI+ mode). Twenty-six DMs were identified, including 25 upregulated and 1 downregulated in the T1D group, mainly involving Acylcarnitines and xanthine metabolites. LASSO regression selected Hydroxyhexadecanoyl carnitine, Propionylcarnitine, and Valerylcarnitine as candidate markers. In the rat model, Hydroxyhexadecanoyl carnitine and Valerylcarnitine demonstrated strong diagnostic performance, with AUCs of 0.9383 (95% CI: 0.8786-0.9980) and 0.8395 (95% CI: 0.7451-0.9338), respectively (P< 0.01). Conclusion: Hydroxyhexadecanoyl carnitine and Valerylcarnitine are closely linked to altered lipid oxidation in T1D and show strong potential as diagnostic biomarkers. These findings provide new insights into the metabolic basis of T1D and offer promising targets for early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.